文献速递银屑病与炎症性皮肤病

银屑病与银屑病关节炎患者的治疗使用与满意度:NORdic银屑病与银屑病关节炎患者调查(NORPAPP)结果

Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP).
PubMed 文献 · J Eur Acad Dermatol Venereol · 2018-11-28

NORPAPP调查随机抽取瑞典、丹麦和挪威22050名成人,1264名自报医生诊断银屑病和/或银屑病关节炎者受邀,96.6%回应。仅银屑病者14.6%使用系统治疗(生物制剂8.1%),银屑病关节炎者58.5%(生物制剂31.8%);认为疾病严重者生物制剂使用26.8% vs 非严重者6.7%。

要点

  • 仅银屑病受访者14.6%使用系统治疗,其中生物制剂8.1%;银屑病关节炎受访者58.5%使用系统治疗,其中生物制剂31.8%。
  • 认为疾病严重者生物制剂使用26.8% vs 非严重者6.7%;患者组织成员40.7% vs 非成员6.9%。
  • 45-75岁受访者生物制剂经验8.1%,低于18-44岁的21.5%;前者对系统治疗长期健康风险更多回答「不知道」(66.7-72.9%)。

核心结论

  • 从患者角度看,斯堪的纳维亚相当数量严重银屑病/银屑病关节炎患者可能未获得最佳治疗,尤其是老年患者;三分之一有严重症状的受访者从未与医生讨论过系统治疗。

研究设计与样本

  • NORPAPP调查随机选取瑞典、丹麦和挪威YouGov小组的22050名成人,询问是否患有银屑病/银屑病关节炎;1264名自报医生诊断者受邀参加完整调查,96.6%回应。

主要发现

  • 仅银屑病受访者中14.6%报告使用系统治疗(生物制剂8.1%),银屑病关节炎受访者中58.5%报告使用系统治疗(生物制剂31.8%)。
  • 认为疾病严重者报告生物制剂治疗26.8% vs 非严重者6.7%;患者组织成员40.7% vs 非成员6.9%。
  • 银屑病关节炎受访者、认为疾病严重者及患者组织成员报告与医生讨论系统治疗的比例显著更高(P < 0.05),但35.2%认为疾病严重者从未与医生讨论过系统治疗。
  • 45-75岁受访者报告生物制剂经验8.1%,低于18-44岁受访者的21.5%;老年受访者对系统治疗长期健康风险更多回答「不知道」(多数66.7-72.9%)。

关键数值与推荐

  • 仅银屑病受访者系统治疗使用14.6%(生物制剂8.1%);银屑病关节炎受访者系统治疗使用58.5%(生物制剂31.8%)。
  • 认为疾病严重者生物制剂使用26.8% vs 非严重者6.7%;患者组织成员40.7% vs 非成员6.9%。
  • 45-75岁受访者生物制剂经验8.1% vs 18-44岁受访者21.5%;老年受访者对系统治疗风险回答「不知道」的比例为66.7-72.9%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are scarce data in Scandinavia about treatment satisfaction among patients with psoriasis (PsO) and/or psoriatic arthritis (PsA). The number of patients receiving systemic treatment is unknown. OBJECTIVE: To describe patients' experience of treatments for PsO/PsA in Sweden, Denmark and Norway, addressing communication with physicians, satisfaction with treatment and concerns regarding treatment options. METHODS: The NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP) asked 22 050 adults (randomly selected from the YouGov panels in Sweden, Denmark and Norway) whether they had PsO/PsA. A total of 1264 individuals who reported physician-diagnosed PsO/PsA were invited to participate in the full survey; 96.6% responded positively. RESULTS: Systemic treatment use was reported by 14.6% (biologic: 8.1%) of respondents with PsO only and by 58.5% (biologic: 31.8%) of respondents with PsA. Biologic treatments were more frequently reported by respondents considering their disease severe (26.8% vs 6.7% non-severe) and those who were members of patient organizations (40.7% vs 6.9% non-members). Discussing systemic treatments with their physician was reported significantly more frequently by respondents with PsA, those perceiving their disease as severe (although 35.2% had never discussed systemic treatment with their physician) and those reporting being a member of a patient organization (P < 0.05). Many respondents reported health risk concerns and dissatisfaction with their treatment. Of special interest was that respondents aged 45-75 years reported less experience with biologics (8.1%) than those aged 18-44 years (21.5%). The older respondents also reported more uncertainty regarding long-term health risks related to systemic treatments (most [66.7-72.9%] responded 'do not know' when asked about the risk of systemic options). CONCLUSION: It appears likely that substantial numbers of Scandinavians suffering from severe PsO/PsA are not receiving optimal treatment from a patient perspective, particularly older patients. Also, one-third of respondents with severe symptoms had never discussed systemic treatment with a physician.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Tveit KS, Duvetorp A, Østergaard M, et al. Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP). J Eur Acad Dermatol Venereol. 2018. PMID: 30242921. doi:10.1111/jdv.15252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。